These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29966204)

  • 1. Do Cardiometabolic Risk Factors Influence Amyloid, Tau, and Neuronal Function in APOE4 Carriers and Non-Carriers in Alzheimer's Disease Trajectory?
    Femminella GD; Taylor-Davies G; Scott J; Edison P;
    J Alzheimers Dis; 2018; 64(3):981-993. PubMed ID: 29966204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship Between Body Mass Index, ApoE4 Status, and PET-Based Amyloid and Neurodegeneration Markers in Amyloid-Positive Subjects with Normal Cognition or Mild Cognitive Impairment.
    Blautzik J; Kotz S; Brendel M; Sauerbeck J; Vettermann F; Winter Y; Bartenstein P; Ishii K; Rominger A;
    J Alzheimers Dis; 2018; 65(3):781-791. PubMed ID: 28697560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment-data from the Dementia Competence Network.
    Benson GS; Bauer C; Hausner L; Couturier S; Lewczuk P; Peters O; Hüll M; Jahn H; Jessen F; Pantel J; Teipel SJ; Wagner M; Schuchhardt J; Wiltfang J; Kornhuber J; Frölich L
    J Neural Transm (Vienna); 2022 Jun; 129(5-6):477-486. PubMed ID: 35061102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels.
    Steward A; Biel D; Dewenter A; Roemer S; Wagner F; Dehsarvi A; Rathore S; Otero Svaldi D; Higgins I; Brendel M; Dichgans M; Shcherbinin S; Ewers M; Franzmeier N
    JAMA Neurol; 2023 Dec; 80(12):1295-1306. PubMed ID: 37930695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing predictors of conversion and decline in mild cognitive impairment.
    Landau SM; Harvey D; Madison CM; Reiman EM; Foster NL; Aisen PS; Petersen RC; Shaw LM; Trojanowski JQ; Jack CR; Weiner MW; Jagust WJ;
    Neurology; 2010 Jul; 75(3):230-8. PubMed ID: 20592257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.
    Alexopoulos P; Guo LH; Jiang M; Bujo H; Grimmer T; Förster S; Drzezga A; Kurz A; Perneczky R
    J Alzheimers Dis; 2013; 36(2):401-8. PubMed ID: 23609762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort.
    Caroli A; Frisoni GB;
    Neurobiol Aging; 2010 Aug; 31(8):1263-74. PubMed ID: 20538373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.
    Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S
    J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β.
    Therriault J; Benedet AL; Pascoal TA; Mathotaarachchi S; Chamoun M; Savard M; Thomas E; Kang MS; Lussier F; Tissot C; Parsons M; Qureshi MNI; Vitali P; Massarweh G; Soucy JP; Rej S; Saha-Chaudhuri P; Gauthier S; Rosa-Neto P
    JAMA Neurol; 2020 Apr; 77(4):470-479. PubMed ID: 31860000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of fast decline in amyloid positive mild cognitive impairment patients using multimodal biomarkers.
    Jang H; Park J; Woo S; Kim S; Kim HJ; Na DL; Lockhart SN; Kim Y; Kim KW; Cho SH; Kim SJ; Seong JK; Seo SW;
    Neuroimage Clin; 2019; 24():101941. PubMed ID: 31376643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
    Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
    Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Thioredoxin-80 is associated with age, ApoE4, and neuropathological biomarkers in Alzheimer's disease: a potential early sign of AD.
    Goikolea J; Gerenu G; Daniilidou M; Mangialasche F; Mecocci P; Ngandu T; Rinne J; Solomon A; Kivipelto M; Cedazo-Minguez A; Sandebring-Matton A; Maioli S
    Alzheimers Res Ther; 2022 Feb; 14(1):37. PubMed ID: 35209952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers.
    Chételat G; Fouquet M
    Rev Neurol (Paris); 2013 Oct; 169(10):729-36. PubMed ID: 24016463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlations between APOE4 allele and regional amyloid and tau burdens in cognitively normal older individuals.
    Hong YJ; Kim CM; Lee JH; Sepulcre J
    Sci Rep; 2022 Aug; 12(1):14307. PubMed ID: 35995824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
    Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
    Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do Tau Deposition and Glucose Metabolism Dissociate in Alzheimer's Disease Trajectory?
    Nowell J; Raza S; Livingston NR; Sivanathan S; Gentleman S; Edison P
    J Alzheimers Dis; 2024; 101(3):987-999. PubMed ID: 39302365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline.
    Montagne A; Nation DA; Sagare AP; Barisano G; Sweeney MD; Chakhoyan A; Pachicano M; Joe E; Nelson AR; D'Orazio LM; Buennagel DP; Harrington MG; Benzinger TLS; Fagan AM; Ringman JM; Schneider LS; Morris JC; Reiman EM; Caselli RJ; Chui HC; Tcw J; Chen Y; Pa J; Conti PS; Law M; Toga AW; Zlokovic BV
    Nature; 2020 May; 581(7806):71-76. PubMed ID: 32376954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.